2 enrolling by invitation. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Enrolling by invitation 2 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma anti-CD19 CAR-NK cells - Refractory/Recurrent Central Nervous System Lymphoma | Phase 1 | Enrolling by invitation | Second Affiliated Hospital, Zhejiang University, School of Medicine | 42 | 2025-03-01 | 2025-08-15 |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
Recurrence (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1)
Disease Attributes (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Chronic Disease (1) · Hematologic Diseases (1) · Leukemia (1)
Cyclophosphamide (1) · fludarabine (1)
Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · University of Maryland, Baltimore (1)
China (1) · United States (1)